Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity

mAbs

Volumn 5, Issue 3, 2013, Pages 418-431

  Shen, Yang ^a   Zeng, Lin ^a   Zhu, Aiping ^a   Blanc, Tim ^a   Patel, Dipa ^a   Pennello, Anthony ^a   Bari, Amtul ^a   Ng, Stanley ^a   Persaud, Kris ^a   Kang, Yun Kenneth ^a   Balderes, Paul ^a   Surguladze, David ^a   Hindi, Sagit ^a   Zhou, Qinwei ^a   Ludwig, Dale L ^a   Snavely, Marshall ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antibody; Disulfide bond; IgG1; IgG1 ; Lambda light chain; Lc; Light chain; Serine; Stability and serine deletion

Indexed keywords

CYSTEINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; SERINE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PROTEIN BINDING;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DISULFIDE BOND; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; LIGHT CHAIN; MALE; MOUSE; NONHUMAN; NUCLEOPHILICITY; PH; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STABILITY; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS; TEMPERATURE STRESS; X RAY CRYSTALLOGRAPHY; ADVERSE EFFECTS; AMINO ACID SEQUENCE; ANIMAL; CHO CELL LINE; CRICETULUS; GENETICS; HAMSTER; HEAT; HEK293 CELL LINE; HUMAN; METABOLISM; MUTATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CHO CELLS; CRICETINAE; CRICETULUS; CYSTEINE; HEK293 CELLS; HOT TEMPERATURE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAINS; MUTAGENESIS, SITE-DIRECTED; MUTATION; PROTEIN BINDING; PROTEIN STABILITY; SERINE;

EID: 84877889150     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.24291     Document Type: Article

References (54)

1. Orfila C, Rakotoarivony J, Manuel Y, Suc JM. Immunofluorescence characterization of light chains in human nephropathies. Virchows Arch A Pathol Anat Histopathol 1988; 412:591-4; PMID:3129870; http://dx.doi.org/10.1007/ BF00844295
2. Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 2006; 24:1241-52; PMID:17033665; http://dx.doi. org/10.1038/nbt1252
3. Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26:985-90; PMID:18779806; http://dx.doi.org/10.1038/nbt0908-985
4. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6:349-56; PMID:17431406; http://dx.doi.org/10.1038/nrd2241
5. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol 2009; 27:331-7; PMID:19352366; http://dx.doi. org/10.1038/nbt0409-331
6. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226-34; PMID:19247305; http://dx.doi. org/10.1038/nrd2804
7. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343-57; PMID:16622479; http://dx.doi.org/10.1038/nri1837
8. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345-52; PMID:20414207; http://dx.doi.org/10.1038/nri2747
9. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413-5; PMID:22531442; http://dx.doi.org/10.4161/mabs.19931
10. http://www.immunologylink.com/FDA-APP-Abs.html. 2011
11. Woloschak GE, Krco CJ. Regulation of kappa/lambda immunoglobulin light chain expression in normal murine lymphocytes. Mol Immunol 1987; 24:751-7; PMID:3116408; http://dx.doi.org/10.1016/0161-5890(87)90058-7
12. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63:8912-21; PMID:14695208
13. Stohl W, Hilbert DM. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol 2012; 30:69-77; PMID:22231104; http://dx.doi.org/10.1038/nbt.2076
14. Liu H, Chumsae C, Gaza-Bulseco G, Hurkmans K, Radziejewski CH. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. Anal Chem 2010; 82:5219-26; PMID:20491447; http://dx.doi. org/10.1021/ac100575n
15. Montaño RF, Morrison SL. Influence of the isotype of the light chain on the properties of IgG. J Immunol 2002; 168:224-31; PMID:11751966
16. Li XQ, Zhang T, Donnelly D. Selective loss of cysteine residues and disulphide bonds in a potato proteinase inhibitor II family. PLoS One 2011; 6:e18615; PMID:21494600; http://dx.doi.org/10.1371/journal. pone.0018615
17. Grey HM. Presence of L-L interchain disulfide bonds in reconstituted gamma G molecules. J Immunol 1969; 102:848-51; PMID:5768193
18. Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27:767-71; PMID:19620983; http://dx.doi. org/10.1038/nbt.1553
19. Schuurman J, Perdok GJ, Gorter AD, Aalberse RC. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol 2001; 38:1-8; PMID:11483205; http://dx.doi.org/10.1016/S0161-5890(01) 00050-5
20. Guo A, Han M, Martinez T, Ketchem RR, Novick S, Jochheim C, et al. Electrophoretic evidence for the presence of structural isoforms specific for the IgG2 isotype. Electrophoresis 2008; 29:2550-6; PMID:18494039; http://dx.doi.org/10.1002/elps.200800083
21. Wypych J, Li M, Guo A, Zhang Z, Martinez T, Allen MJ, et al. Human IgG2 antibodies display disulfidemediated structural isoforms. J Biol Chem 2008; 283:16194-205; PMID:18339624; http://dx.doi. org/10.1074/jbc.M709987200
22. Martinez T, Guo A, Allen MJ, Han M, Pace D, Jones J, et al. Disulfide connectivity of human immunoglobulin G2 structural isoforms. Biochemistry 2008; 47:7496-508; PMID:18549248; http://dx.doi.org/10.1021/bi800576c
23. Zhang B, Harder AG, Connelly HM, Maheu LL, Cockrill SL. Determination of Fab-hinge disulfide connectivity in structural isoforms of a recombinant human immunoglobulin G2 antibody. Anal Chem 2010; 82:1090-9; PMID:20039682; http://dx.doi. org/10.1021/ac902466z
24. Brych SR, Gokarn YR, Hultgen H, Stevenson RJ, Rajan R, Matsumura M. Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation. J Pharm Sci 2010; 99:764-81; PMID:19691118
25. Van Buren N, Rehder D, Gadgil H, Matsumura M, Jacob J. Elucidation of two major aggregation pathways in an IgG2 antibody. J Pharm Sci 2009; 98:3013-30; PMID:18680168; http://dx.doi.org/10.1002/jps.21514
26. Natvig JB, Kunkel HG. Human immunoglobulins: classes, subclasses, genetic variants, and idiotypes. Adv Immunol 1973; 16:1-59; PMID:4125921; http://dx.doi.org/10.1016/S0065-2776(08)60295-3
27. Liu H, Zhong S, Chumsae C, Radziejewski C, Hsieh CM. Effect of the light chain C-terminal serine residue on disulfide bond susceptibility of human immunoglobulin G1λ. Anal Biochem 2011; 408:277-83; PMID:20869344; http://dx.doi.org/10.1016/j. ab.2010.09.025
28. Yan B, Boyd D, Kaschak T, Tsukuda J, Shen A, Lin Y, et al. Engineering upper hinge improves stability and effector function of a human IgG1. J Biol Chem 2012; 287:5891-7; PMID:22203673; http://dx.doi. org/10.1074/jbc.M111.311811
29. Debler EW, Ito S, Seebeck FP, Heine A, Hilvert D, Wilson IA. Structural origins of efficient proton abstraction from carbon by a catalytic antibody. Proc Natl Acad Sci U S A 2005; 102:4984-9; PMID:15788533; http://dx.doi.org/10. 1073/pnas.0409207102
30. Lewis AP, Lemon SM, Barber KA, Murphy P, Parry NR, Peakman TC, et al. Rescue, expression, and analysis of a neutralizing human anti-hepatitis A virus monoclonal antibody. J Immunol 1993; 151:2829-38; PMID:8395549
31. Prabakaran P, Gan J, Feng Y, Zhu Z, Choudhry V, Xiao X, et al. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem 2006; 281:15829-36; PMID:16597622; http://dx.doi.org/10.1074/jbc. M600697200
32. Faber C, Shan L, Fan Z, Guddat LW, Furebring C, Ohlin M, et al. Three-dimensional structure of a human Fab with high affinity for tetanus toxoid. Immunotechnology 1998; 3:253-70; PMID:9530559; http://dx.doi.org/10. 1016/S1380-2933(97)10003-3
33. Malia TJ, Obmolova G, Almagro JC, Gilliland GL, Teplyakov A. Crystal structure of human germline antibody 3-23/B3. Mol Immunol 2011; 48:1586-8; PMID:21605907; http://dx.doi.org/10.1016/j. molimm.2011.04.020
34. Wong JW, Hogg PJ. Analysis of disulfide bonds in protein structures. J Thromb Haemost 2010; PMID:20456749; http://dx.doi.org/10.1111/j.1538-7836.2010. 03894.x
35. Kuang Z, Yao S, Xu Y, Lewis RS, Low A, Masters SL, et al. SPRY domain-containing SOCS box protein 2: crystal structure and residues critical for protein binding. J Mol Biol 2009; 386:662-74; PMID:19154741; http://dx.doi.org/10.1016/j.jmb.2008.12.078
36. Schmidt B, Hogg PJ. Search for allosteric disulfide bonds in NMR structures. BMC Struct Biol 2007; 7:49; PMID:17640393; http://dx.doi.org/10. 1186/1472-6807-7-49
37. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 2010; 66:486-501; PMID:20383002; http://dx.doi.org/10.1107/S0907444910007493
38. The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC
39. Harris TK, Turner GJ. Structural basis of perturbed pKa values of catalytic groups in enzyme active sites. IUBMB Life 2002; 53:85-98; PMID:12049200; http://dx.doi.org/10.1080/15216540211468
40. Kellner R, Mermet JM, Otto M, Widmer HM, eds. Analytical Chemistry. Weinheim, NY: Wiley-VCH, 1998
41. Dall'Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol 2006; 177:1129-38; PMID:16818770
42. Dorai H, Wesolowski JS, Gillies SD. Role of interheavy and light chain disulfide bonds in the effector functions of human immunoglobulin IgG1. Mol Immunol 1992; 29:1487-91; PMID:1454066; http://dx.doi.org/10.1016/0161-5890(92) 90222-J
43. Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, Frangioni JV, et al. A modular IgGscFv bispecific antibody topology. Protein Eng Des Sel 2010; 23:221-8; PMID:20019028; http://dx.doi. org/10.1093/protein/gzp077
44. Spangler JB, Manzari MT, Rosalia EK, Chen TF, Wittrup KD. Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. J Mol Biol 2012; 422:532-44; PMID:22706026; http://dx.doi.org/10.1016/j. jmb.2012.06.014
45. Hendershot LM. Immunoglobulin heavy chain and binding protein complexes are dissociated in vivo by light chain addition. J Cell Biol 1990; 111:829-37; PMID:2118144; http://dx.doi.org/10.1083/jcb.111.3.829
46. Reddy P, Sparvoli A, Fagioli C, Fassina G, Sitia R. Formation of reversible disulfide bonds with the protein matrix of the endoplasmic reticulum correlates with the retention of unassembled Ig light chains. EMBO J 1996; 15:2077-85; PMID:8641273
47. Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 1994; 372:379-83; PMID:7969498; http://dx.doi.org/10.1038/372379a0
48. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281:23514-24; PMID:16793771; http://dx.doi. org/10.1074/jbc.M604292200
49. Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 2002; 169:5171-80; PMID:12391234
50. Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 2006; 18:1759-69; PMID:17077181; http://dx.doi.org/10.1093/intimm/dxl110
51. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990; 215:403-10; PMID:2231712
52. Bernstein FC, Koetzle TF, Williams GJ, Meyer EF Jr., Brice MD, Rodgers JR, et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. Arch Biochem Biophys 1978; 185:584-91; PMID:626512; http://dx.doi.org/10.1016/0003-9861(78)90204-7
53. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007; 23:2947-8; PMID:17846036; http://dx.doi.org/10.1093/bioinformatics/btm404
54. Holm L, Park J. Dali Lite workbench for protein structure comparison. Bioinformatics 2000; 16:566-7; PMID:10980157; http://dx.doi.org/10.1093/ bioinformatics/16.6.566